The Newsroom

Find out the latest about Calidi. Announcements, press coverage, publications, and company info—it’s all here.

Press Release

Calidi Biotherapeutics Presents Data Supporting RTNova Systemic Technology to Target Metastatic Lung Cancer

Calidi Biotherapeutics presents promising data on RTNova™, a novel systemic virotherapy technology designed to target metastatic lung cancer and other advanced cancers by overcoming immune clearance and enhancing therapeutic targeting

Discover More

Press Release

event

NeuroNova

Supernova

RTNova

Calidi Biotherapeutics Presents Data Supporting RTNova Systemic Technology to Target Metastatic Lung Cancer

November 18, 2024

Press Release

event

NeuroNova

Supernova

RTNova

Calidi Biotherapeutics Announces Closing of $7.5 Million Public Offering of Common Stock

November 15, 2024

Press Release

event

NeuroNova

Supernova

RTNova

Calidi Biotherapeutics Announces Pricing of $7.5 Million Public Offering of Common Stock

November 14, 2024

Press Release

event

NeuroNova

Supernova

RTNova

Calidi Biotherapeutics Announces Proposed Public Offering

November 13, 2024

Publication

event

RTNova

NeuroNova

Supernova

RTNova

Transforming all Tumor Sites: The Power of Systemic Enveloped Virotherapy

SITC 2024

November 13, 2024

Press Release

event

NeuroNova

Supernova

RTNova

Calidi Biotherapeutics Reports Third Quarter 2024 Operating and Financial Results

Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today reported its operating and financial results for the third quarter ended September 30, 2024

November 12, 2024

Press Release

Calidi Biotherapeutics Announces Global Oncolytic Virus-based Immunotherapy License to VetStem Biopharma for its Pioneering Treatment of Cancer in the Veterinary Field

July 10, 2019

Discover More

Press Release

Calidi Biotherapeutics Announces The Appointment of Medical Oncologist and Expert in Oncolytic Immunotherapies, Dr. Dmitriy Zamarin to Their Scientific Advisory Board

June 3, 2019

Discover More

Press Release

Calidi Biotherapeutics Announces The Appointment Of Seasoned Biotech Executive Dr. Ashok Srivastava To Their Scientific Advisory Board

May 30, 2019

Discover More

Press Release

Calidi Biotherapeutics Announces A Collaborative Study With The National Institutes Of Health (NIH) On The Therapeutic Potential Of Oncolytic Viruses Delivered By Mesenchymal Stem Cells

May 28, 2019

Discover More

Press Release

Calidi Biotherapeutics Releases Recent Interviews of CEO Allan Camaisa

April 15, 2019

Discover More

Press Release

Calidi Biotherapeutics Launches Scientific and Medical Advisory Board

January 4, 2019

Discover More

Publication

event

NeuroNova (NNV)

NeuroNova

Supernova

Rationale for the clinical use of adipose-derived mesenchymal stem cells for COVID-19 patients

The Journal of Translational Medicine

May 18, 2020

Publication

event

NeuroNova (NNV)

NeuroNova

Supernova

ASCO-SITC Clinical Immuno-Oncology Symposium February 6-8, 2020 Orlando, Florida.

Abstract 21: A cell-based platform to potentiate oncolytic virus therapies

February 6, 2020

Publication

event

SuperNova (SNV)

NeuroNova

Supernova

A cell-based platform to potentiate oncolytic virus: Potential approach for cancer therapies.

Journal of Clinical Oncology

February 4, 2020

Publication

event

NeuroNova (NNV)

NeuroNova

Supernova

First-in-human study of TK-positive oncolytic vaccinia virus delivered by adipose stromal vascular fraction cells

The Journal of Translational Medicine

August 19, 2019

Publication

event

SuperNova (SNV)

NeuroNova

Supernova

First-in-human study of TK-positive oncolytic vaccinia virus delivered by adipose stromal vascular fraction cells

The Journal of Translational Medicine

August 19, 2019

Publication

event

SuperNova (SNV)

NeuroNova

Supernova

Delivery of oncolytic vaccinia virus by matched allogeneic stem cells overcomes critical innate and adaptive immune barriers

The Journal of Translational Medicine

March 27, 2019

Media

Good Morning San Diego, Calidi Bio Treatments Discussed

April 13, 2019

Discover More

Media

KUSI San Diego News - Calidi Bio CEO, Allan Camaisa Interviewed

April 12, 2019

Discover More

In The News

Calidi Biotherapeutics: A Promising Player in the Cancer Treatment Market

Calidi Biotherapeutics Inc (NYSE: CLDI) is making waves in the biotech industry with its innovative approach to cancer treatment. The company utilizes allogeneic stem cells to deliver oncolytic viruses directly to tumors, offering new hope for patients.

October 9, 2023

Discover More

In The News

Analyst Bullish On Calidi Biotherapeutics, Newly Listed Cancer Treatment Player

Baird initiates coverage on Calidi Biotherapeutics Inc CLDI, which uses allogeneic stem cells to deliver oncolytic viruses to tumors for cancer treatment. Just a month back, Calidi Biotherapeutics became the latest biotech to take the special purpose acquisition company route to the public market

October 9, 2023

Discover More

A talented, seasoned group of world-class executives, doctors, and scientists producing revolutionary work.

Learn more

The Newsroom

Calidi Biotherapeutics Presents Data Supporting RTNova Systemic Technology to Target Metastatic Lung Cancer

Calidi Biotherapeutics Presents Data Supporting RTNova Systemic Technology to Target Metastatic Lung Cancer

Calidi Biotherapeutics Announces Closing of $7.5 Million Public Offering of Common Stock

Calidi Biotherapeutics Announces Pricing of $7.5 Million Public Offering of Common Stock

Calidi Biotherapeutics Announces Proposed Public Offering

Transforming all Tumor Sites: The Power of Systemic Enveloped Virotherapy

Calidi Biotherapeutics Reports Third Quarter 2024 Operating and Financial Results

Calidi Biotherapeutics Announces Global Oncolytic Virus-based Immunotherapy License to VetStem Biopharma for its Pioneering Treatment of Cancer in the Veterinary Field

Calidi Biotherapeutics Announces The Appointment of Medical Oncologist and Expert in Oncolytic Immunotherapies, Dr. Dmitriy Zamarin to Their Scientific Advisory Board

Calidi Biotherapeutics Announces The Appointment Of Seasoned Biotech Executive Dr. Ashok Srivastava To Their Scientific Advisory Board

Calidi Biotherapeutics Announces A Collaborative Study With The National Institutes Of Health (NIH) On The Therapeutic Potential Of Oncolytic Viruses Delivered By Mesenchymal Stem Cells

Calidi Biotherapeutics Releases Recent Interviews of CEO Allan Camaisa

Calidi Biotherapeutics Launches Scientific and Medical Advisory Board

Rationale for the clinical use of adipose-derived mesenchymal stem cells for COVID-19 patients

ASCO-SITC Clinical Immuno-Oncology Symposium February 6-8, 2020 Orlando, Florida.

A cell-based platform to potentiate oncolytic virus: Potential approach for cancer therapies.

First-in-human study of TK-positive oncolytic vaccinia virus delivered by adipose stromal vascular fraction cells

First-in-human study of TK-positive oncolytic vaccinia virus delivered by adipose stromal vascular fraction cells

Delivery of oncolytic vaccinia virus by matched allogeneic stem cells overcomes critical innate and adaptive immune barriers

Good Morning San Diego, Calidi Bio Treatments Discussed

KUSI San Diego News - Calidi Bio CEO, Allan Camaisa Interviewed

Calidi Biotherapeutics: A Promising Player in the Cancer Treatment Market

Analyst Bullish On Calidi Biotherapeutics, Newly Listed Cancer Treatment Player

All Courses

A talented, seasoned group of world-class executives, doctors, and scientists producing revolutionary work.